Naloxone Switch: Door Opener For Other NDAs That Swing On Consumer Education
This article was originally published in The Pink Sheet Daily
Executive Summary
Health care professionals provide naloxone in an outpatient setting in “highly successful programs,” but FDA approval of a switch rests on whether “just putting the drug on the store shelf for anyone to purchase with no training or guidance on use” will be safe, says nonprescription drug division head Theresa Michele.
You may also be interested in...
Bring Naloxone To Opioid Overdoses: FDA Crowd-Sources Smartphone Apps
FDA announces $40,000 Naloxone App Competition at the start of Prescription Opioid and Heroin Epidemic Awareness Week through Sept. 23, when registration open for the competition, which closes Oct. 7.
Naloxone Costs Could Temper Non-Rx Access Even As Distribution Spreads
CVS in 31 states offers naloxone from pharmacists without a prescription and Walgreens offers it in 14, with plans to more than double the program this year. Whether from pharmacists or OTC, "an affordable price is essential if this is to reach the people who need it," says harm reduction advocate Scott Burris.
Naloxone Costs Could Temper Non-Rx Access Even As Distribution Spreads
CVS in 31 states offers naloxone from pharmacists without a prescription and Walgreens offers it in 14, with plans to more than double the program this year. Whether from pharmacists or OTC, "an affordable price is essential if this is to reach the people who need it," says harm reduction advocate Scott Burris.